Crescent Biopharma, Inc.
- CBIO · Nasdaq
- Pharmaceutical Preparations
- Waltham, MA
- 44 employees
- CIK 0001253689
Updated from SEC filings through
Top things to know
Executives
- Joshua T. Brumm Chief Executive Officer 4, 2026-09-18
- Richard William Scalzo Chief Financial Officer 4, 2026-09-18
- Richard Scalzo Chief Financial Officer 10-K, 2026-02-26
-
Jonathan McNeill President and COO 4, 2026-09-18 - Jan Pinkas Chief Scientific Officer 4, 2026-09-18
- Ellie Eunkyung Im Chief Medical Officer 4, 2026-09-18
Crescent Biopharma, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Waltham, MA. It trades as CBIO on Nasdaq. Revenue was $10.8M in the fiscal year ending December 31, 2025, +108340.0% from the year before. It reported about 44 employees. Joshua T. Brumm is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $10.8M 10-K, 2026-02-26 | Not on file | $10K 10-K, 2025-02-13 | $75K 10-K, 2024-03-27 | $1.2M 10-K, 2024-03-27 |
| Operating income | -$153M 10-K, 2026-02-26 | -$40.0M 10-K, 2025-02-13 | -$39.3M 10-K, 2025-02-13 | -$47.4M 10-K, 2024-03-27 | -$63.4M 10-K, 2024-03-27 |
| SG&A | $25.4M 10-K, 2026-02-26 | $18.2M 10-K, 2025-02-13 | $19.2M 10-K, 2025-02-13 | $19.1M 10-K, 2024-03-27 | $17.1M 10-K, 2024-03-27 |
| Net income | -$154M 10-K, 2026-02-26 | -$37.9M 10-K, 2025-02-13 | -$36.9M 10-K, 2025-02-13 | -$46.7M 10-K, 2024-03-27 | -$63.4M 10-K, 2024-03-27 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Joshua T. Brumm | Chief Executive Officer | 4, 2026-09-18 |
| Richard William Scalzo Chief Financial Officer | Chief Financial Officer | 4, 2026-09-18 |
| Richard Scalzo | Chief Financial Officer | 10-K, 2026-02-26 |
| Jonathan McNeill | President and COO | 4, 2026-09-18 |
| Jan Pinkas CSO with extensive large molecule/ADC Oncology drug development | Chief Scientific Officer | 4, 2026-09-18 |
| Ellie Eunkyung Im | Chief Medical Officer | 4, 2026-09-18 |
 Ryan Lynch | Treasurer, Senior Vice President of Finance and Chief Accounting Officer | 10-K, 2026-02-26 |
| Christopher Grant Doughty | Chief Business Officer | 4, 2025-12-17 |
| Alexandra Balcom | Director | 10-K, 2026-02-26 |
| David Lubner | Director | 10-K, 2026-02-26 |
| Susan Moran | Director | 10-K, 2026-02-26 |
What Crescent Biopharma, Inc. does
We were incorporated under the laws of the State of Delaware in 2003., is a biotechnology company that is the result of a reverse recapitalization transaction with a private company named Crescent Biopharma, Inc. (“Pre-Merger Crescent”). Prior to the reverse recapitalization transaction, Pre-Merger Crescent was established and incorporated under the laws of the state of Delaware on September 19, 2024.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 37.1 million (as of July 27, 2026) | 10-Q, July 30, 2026 |
|---|---|---|
| Public float | $177M (as of June 30, 2025) | 10-K, February 26, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, July 30, 2026 |
| Latest proxy statement | Meeting June 2, 2026 (filed April 21, 2026) | DEF 14A, April 21, 2026 |
| Auditor | PricewaterhouseCoopers LLP (Boston, Massachusetts) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 18, 2026 | Joshua T. Brumm Chief Executive Officer | Sale | 9,447 | $160K | Form 4, September 18, 2026 |
| September 18, 2026 | Jonathan McNeill President and COO | Sale | 4,570 | $77K | Form 4, September 18, 2026 |
| September 16, 2026 | Ryan Lynch See Remarks | Sale | 240 | $4K | Form 4, September 18, 2026 |
| September 16, 2026 | Jan Pinkas Chief Scientific Officer | Sale | 658 | $12K | Form 4, September 18, 2026 |
| September 16, 2026 | Ellie Eunkyung Im Chief Medical Officer | Sale | 623 | $11K | Form 4, September 18, 2026 |
| September 16, 2026 | Richard William Scalzo Chief Financial Officer | Sale | 568 | $10K | Form 4, September 18, 2026 |
| September 16, 2026 | Barbara Harlin Bispham See Remarks | Sale | 620 | $11K | Form 4, September 18, 2026 |
| July 16, 2026 | Tomas Kiselak Director | Buy | 853,450 | $12.4M | Form 4, July 20, 2026 |
Recent 8-K events
- 8-K filed 2026-10-15
- Item 8.01 Other events
- 8-K filed 2026-07-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-15
- Item 8.01 Other events
- 8-K filed 2026-07-14
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-03
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-26
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-12-04
- Item 1.01 Entry into a material definitive agreement
- Item 3.02 Unregistered sales of equity securities
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2025-11-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-07-31
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Crescent Biopharma, Inc.
- What does Crescent Biopharma, Inc. do?
- In its own words, from Item 1 of its 10-K: "We were incorporated under the laws of the State of Delaware in 2003., is a biotechnology company that is the result of a reverse recapitalization transaction with a private company named Crescent Biopharma, Inc. (“Pre-Merger Crescent”). Prior to the reverse recapitalization transaction, Pre-Merger Crescent was established and incorporated under the laws of the state of Delaware on September 19, 2024."
- What is Crescent Biopharma, Inc.'s revenue?
- $10.8M for the fiscal year ending December 31, 2025, from its 10-K filed February 26, 2026.
- Is Crescent Biopharma, Inc. profitable?
- Crescent Biopharma, Inc. reported net income of -$154M for the fiscal year ending December 31, 2025.
- How many employees does Crescent Biopharma, Inc. have?
- About 44 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Crescent Biopharma, Inc.?
- Joshua T. Brumm, Chief Executive Officer, as named in a 4 filed September 18, 2026.
- Who is the CFO of Crescent Biopharma, Inc.?
- Richard William Scalzo, Chief Financial Officer, as named in a 4 filed September 18, 2026.
- Where is Crescent Biopharma, Inc. headquartered?
- Waltham, MA.
- What is Crescent Biopharma, Inc.'s stock ticker?
- CBIO on Nasdaq.
- What industry is Crescent Biopharma, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Crescent Biopharma, Inc.'s website?
- crescentbiopharma.com. Investor relations: https://investors.crescentbiopharma.com/events-presentations.
- When does Crescent Biopharma, Inc. report earnings next?
- November 14, 2026. Source: estimate_10q_cadence.
- Is Crescent Biopharma, Inc. a public company?
- Yes. Crescent Biopharma, Inc. files with the SEC under CIK 0001253689 and trades as CBIO.
- Who audits Crescent Biopharma, Inc.?
- PricewaterhouseCoopers LLP, Boston, Massachusetts, as named in its latest annual report (10-K).
- How many shares of Crescent Biopharma, Inc. are outstanding?
- 37.1 million shares as of July 27, 2026, from its 10-Q filed July 30, 2026.
- What is Crescent Biopharma, Inc.'s public float?
- $177M as of June 30, 2025, as reported on the cover of its 10-K filed February 26, 2026.
- How many business segments does Crescent Biopharma, Inc. report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed July 30, 2026.
- When is Crescent Biopharma, Inc.'s annual shareholder meeting?
- June 2, 2026, per its proxy statement (DEF 14A) filed April 21, 2026.
- Have Crescent Biopharma, Inc. insiders traded stock recently?
- Since December 4, 2025, officers and directors reported 14 open-market sales worth about $1.5M and 8 purchases worth about $122M on Forms 4 and 5. The most recent: Joshua T. Brumm (Chief Executive Officer) sold 9,447 shares on September 18, 2026.